<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00656695</url>
  </required_header>
  <id_info>
    <org_study_id>iminoral</org_study_id>
    <nct_id>NCT00656695</nct_id>
  </id_info>
  <brief_title>Comparisone of Iminoral Versus Neoral in Prevention of Acute Rejection in Renal Transplantation</brief_title>
  <official_title>The Comparison Between Clinical and Paraclinical Effect of Iminoral Vs Neoral in Prevention of Acute Rejection in the First Year Afer Transplantation in De Novo Renal Transplant Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Imam Khomeini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Imam Khomeini Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cyclosporine is the key drug in organ transplantation. In Iran the investigators have more
      than 2500 new renal transplantation each year and because of this the government pay a huge
      amount of money for subsiding the imported cyclosporine in the form of Neoral. Recently an
      Iranian drug company introduced this drug in the name of Iminoral which has been approved by
      different authorities in Iran and abroad, (including the Ministry of Health in Iran and also
      European Directorate for the Quality of Medicines Certification Unit and FDA(Department of
      Health and Human Services,Center for Drug Evaluation and Research)). The investigators study
      is the first clinical trial to compare the effect of Iminoral versus Neoral in preventing
      acute rejection in renal transplantation and also to compare the side effects of these two
      drugs.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">April 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>transplanted kidney acute rejection</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>cyclosporine side effects</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">208</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>taking Iminoral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>taking Neoral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Iminoral</intervention_name>
    <description>Iminoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoral</intervention_name>
    <description>Neoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. renal transplantation candidates

          2. written consent

          3. not taking participate in any other clinical trial in last 3 months

        Exclusion Criteria:

          1. primary FSGS

          2. hyperoxaluria

          3. age under 18

          4. multi organ transplantation

          5. any malignancy in 5 years

          6. PRA &gt; 25%

          7. use of Tacrolimus

          8. hyper acute rejection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad R Khatami, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Imam Khomeini Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Imam Khomeini Hospital</name>
      <address>
        <city>Tehran</city>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2008</study_first_submitted>
  <study_first_submitted_qc>April 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2008</study_first_posted>
  <last_update_submitted>June 21, 2012</last_update_submitted>
  <last_update_submitted_qc>June 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 22, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Imam Khomeini Hospital</investigator_affiliation>
    <investigator_full_name>Mohammad Reza Khatami</investigator_full_name>
    <investigator_title>Associate professor</investigator_title>
  </responsible_party>
  <keyword>Iminoral</keyword>
  <keyword>Neoral</keyword>
  <keyword>Acute renal transplant rejection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

